Sabine Wilhelm, PhD; Katharine A. Phillips, MD; Jennifer L. Greenberg, PsyD; et al.
free access
JAMA Psychiatry. 2019;76(4):363-373. doi:10.1001/jamapsychiatry.2018.4156
This randomized clinical trial compares the symptom reduction and treatment gain durability between cognitive behavioral therapy or supportive psychotherapy for adults with body dysmorphic disorder.
Daniel E. Falk, PhD; Stephanie S. O’Malley, PhD; Katie Witkiewitz, PhD; et al.
free access
JAMA Psychiatry. 2019;76(4):374-381. doi:10.1001/jamapsychiatry.2018.3079
This secondary data analysis of data from clinical trials evaluates the sensitivity of World Health Organization risk level reduction of alcohol intake as outcomes in alcohol use disorder pharmacotherapy trials.
Joseph F. Hayes, PhD; Andreas Lundin, PhD; Susanne Wicks, PhD; et al.
open access
JAMA Psychiatry. 2019;76(4):382-390. doi:10.1001/jamapsychiatry.2018.3907
This series of within-individual cohort studies assesses whether hydroxylmethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, L-type calcium channel antagonists, and biguanides are associated with reduced rates of psychiatric hospitalization and self-harm in individuals with serious mental illness.
Rebecca J. Schmidt, PhD; Ana-Maria Iosif, PhD; Elizabeth Guerrero Angel, MS; et al.
free access
JAMA Psychiatry. 2019;76(4):391-398. doi:10.1001/jamapsychiatry.2018.3901
This cohort study examines the association between prenatal vitamin use in the early stages of pregnancy and the risk of autism in young children born into families who are genetically susceptible to autism spectrum disorder.
Karmel W. Choi, PhD; Chia-Yen Chen, PhD; Murray B. Stein, MD, MPH; et al.
free access
JAMA Psychiatry. 2019;76(4):399-408. doi:10.1001/jamapsychiatry.2018.4175
This 2-sample mendelian randomization study assesses bidirectional relationships between physical activity and depression among phenotype samples with self-reported and accelerometer-based physical activity and major depressive disorder from nonoverlapping genome-wide association studies.
François Montastruc, MD, PhD; Rui Nie, MSc; Simone Loo, MSc; et al.
free access
JAMA Psychiatry. 2019;76(4):409-417. doi:10.1001/jamapsychiatry.2018.4149
This study examines whether using aripiprazole for the first time or adding it to a treatment regimen lead to serious outcomes for patients with a history of taking antipsychotic medications.
Aaron Reuben, MEM; Jonathan D. Schaefer, MA; Terrie E. Moffitt, PhD; et al.
open access
has multimedia
JAMA Psychiatry. 2019;76(4):418-425. doi:10.1001/jamapsychiatry.2018.4192
This cohort study assesses whether exposure to lead during childhood is associated with lifelong mental health disorder symptoms and difficult personality traits in adulthood.
Gabriella Gobbi, MD, PhD; Tobias Atkin, BA; Tomasz Zytynski, MD; et al.
free access
JAMA Psychiatry. 2019;76(4):426-434. doi:10.1001/jamapsychiatry.2018.4500
This systematic review and meta-analysis examines the association of cannabis use during adolescence with risk of developing subsequent major depression, anxiety, and suicidal behavior in young adulthood.
Qiang Luo, PhD; Qiang Chen, PhD; Wenjia Wang, PhD; et al.
open access
JAMA Psychiatry. 2019;76(4):435-445. doi:10.1001/jamapsychiatry.2018.4126
This imaging genetics study examines genetic variants associated with adolescent brain structure and explores the psychopathologic relevance of such associations in the development of schizophrenia.